ADAMTS13, recombinant-krhn (Adzynma; formerly TAK-755, BAX930, SHP655) (Takeda Pharmaceutical Co. Ltd.) is an intravenous human recombinant A disintegrin and metalloproteinase with thrombospondin motifs 13 (rADAMTS13) indicated for prophylactic or on demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
TOPS System (Premia Spine) for Treatment of Symptomatic Lumbar Spondylolisthesis With Spinal Stenosis
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the TOPS System (Premia Spine) for treatment of symptomatic lumbar spondylolisthesis with spinal stenosis.
AGENT Drug-Coated Balloon (Boston Scientific Corp.) for Coronary In-stent Restenosis
The AGENT Drug-Coated Balloon (Boston Scientific Corp.) is a paclitaxel-coated balloon catheter indicated for treatment of coronary in-stent restenosis (ISR). It is intended to be used after appropriate vessel preparation in adult patients undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.0 millimeters (mm) to 4.0 mm in diameter and lesions up to 26 m…
RevitalVision Perceptual Learning Vision Training Program (Talshir Medical Technologies LTD) for Treatment of Amblyopia
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of RevitalVision for treatment of amblyopia in individuals aged 9 years or older.
dNerva Lung Denervation System (Nuvaira Inc.) for Chronic Obstructive Pulmonary Disease
The dNerva Lung Denervation System (Nuvaira Inc.) is an investigational, bronchoscopic catheter-based pulmonary nerve ablation system proposed to reduce the frequency and severity of chronic obstructive pulmonary disease (COPD) exacerbations.
Afamitresgene Autoleucel (Adaptimmune Therapeutics) for Advanced Synovial Sarcoma
Afamitresgene autoleucel is an investigational autologous engineered T-cell therapy for the treatment of HLA-A*02 positive patients with advanced synovial sarcoma expressing the MAGE-A4 antigen.
aXess Vascular Conduit (Xeltis) for Dialysis Access
The aXess graft (Xeltis) is a synthetic bioresorbable vascular conduit under investigation to establish arteriovenous access for hemodialysis in patients with end-stage renal disease.
Prademagene Zamikeracel (Abeona Therapeutics Inc.) for Recessive Dystrophic Epidermolysis Bullosa
Prademagene zamikeracel (pz-cel; formerly EB-101) (Abeona Therapeutics Inc.) is a gene-corrected epidermal sheet under investigation for the treatment recessive dystrophic epidermolysis bullosa.
CYB003 (Cybin Inc.) Deuterated Psilocybin Analogue for Major Depressive Disorder
CYB003 (Cybin Inc.) is an oral deuterated psilocybin analogue proposed for use in conjunction with supportive psychotherapy for treatment of patients with moderate to severe major depressive disorder who have had an inadequate response to an antidepressant medication.
FSYX Ocular Pressure Adjusting Pump (Balance Ophthalmics Inc.) for Open-Angle Glaucoma
The FSYX Ocular Pressure Adjusting Pump (Balance Ophthalmics Inc.) is an investigational negative pressure eye goggle intended for adjunctive therapy to reduce nocturnal intraocular pressure in patients with open-angle glaucoma and normal daytime intraocular pressure.